Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group
- PMID: 2189084
- DOI: 10.1212/wnl.40.6.971
Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group
Abstract
We describe the interrater variability in the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Two physicians blinded to their previous assessments and to each other's scores consecutively examined 168 patients (545 paired examinations). Perfect agreement on the assignment of the disability scores ranged from 48% (cerebellar functional group) to 69% (EDSS and pyramidal functional group). Only 31% to 62% of this agreement occurred independently of that expected by chance (kappa). With the exception of the cerebellar and sensory functional groups, agreement within 1 step occurred in at least 92% of cases. These findings suggest that differences of a single step on these scales may not reflect an important functional change. We recommend that at least a 2-step change (1.0 point on the EDSS and 2 points on the FS) is needed to be confident of an important change in the degree of disability or response to treatment in this disease.
Comment in
-
EDSS reliability.Neurology. 1991 Feb;41(2 ( Pt 1)):332. doi: 10.1212/wnl.41.2_part_1.332. Neurology. 1991. PMID: 1992392 No abstract available.
Similar articles
-
Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group.Neurology. 1992 Apr;42(4):859-63. doi: 10.1212/wnl.42.4.859. Neurology. 1992. PMID: 1565242
-
Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test.Mult Scler. 2001 Jun;7(3):201-6. doi: 10.1177/135245850100700311. Mult Scler. 2001. PMID: 11475445
-
Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.Mult Scler. 2019 Oct;25(11):1526-1534. doi: 10.1177/1352458518793527. Epub 2018 Aug 24. Mult Scler. 2019. PMID: 30141729
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
On the origin of EDSS.Mult Scler Relat Disord. 2015 Mar;4(2):95-103. doi: 10.1016/j.msard.2015.02.003. Epub 2015 Feb 24. Mult Scler Relat Disord. 2015. PMID: 25787185 Review.
Cited by
-
Advancements in eye movement measurement technologies for assessing neurodegenerative diseases.Front Digit Health. 2024 Jul 4;6:1423790. doi: 10.3389/fdgth.2024.1423790. eCollection 2024. Front Digit Health. 2024. PMID: 39027628 Free PMC article. Review.
-
Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment.Pharmacoecon Open. 2024 Sep;8(5):665-678. doi: 10.1007/s41669-024-00501-x. Epub 2024 Jul 1. Pharmacoecon Open. 2024. PMID: 38949748 Free PMC article.
-
Testing the Validity and Reliability of a Standardized Virtual Examination for Concussion.Neurol Clin Pract. 2024 Oct;14(5):e200328. doi: 10.1212/CPJ.0000000000200328. Epub 2024 Jun 14. Neurol Clin Pract. 2024. PMID: 38895642
-
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.Front Neurol. 2023 Sep 21;14:1265354. doi: 10.3389/fneur.2023.1265354. eCollection 2023. Front Neurol. 2023. PMID: 37808497 Free PMC article.
-
Innovative multidimensional gait evaluation using IMU in multiple sclerosis: introducing the semiogram.Front Neurol. 2023 Sep 15;14:1237162. doi: 10.3389/fneur.2023.1237162. eCollection 2023. Front Neurol. 2023. PMID: 37780706 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical